Part of the multidistrict lawsuit over EpiPen price gouging, which involves racketeering and antitrust claims against Mylan NV, was certified as a class action Thursday by a Kansas federal judge, who also declined to let other EpiPen buyers proceed collectively, reported Bloomberg.
EpiPen, an epinephrine auto-injector that treats potentially fatal allergic reactions, has been a poster child for drug price-gouging since an uproar in 2016 over its increase from $50 a shot to $300.
The sprawling consolidated suit includes parallel proposed class actions on behalf of patients, insurers, and plan sponsors like employers, as well as individual claims by competitors.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI